EUVIMEDEUVIMED entdecken
Crossref

Recompensation After Etiologic Cure in United States Veterans With Hepatitis C Virus–Related Decompensated Cirrhosis

Daniela Goyes, Anahita Rabiee, Nicolas Chong-Lugon, Catherine Mezzacappa, David E Kaplan, Tamar H Taddei, Guadalupe Garcia-Tsao

Clinical Gastroenterology and Hepatology · 2026-08

DOI: 10.1016/j.cgh.2026.08.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-08. Verfasst von Daniela Goyes und 6 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Diseases Section, VA Connecticut Healthcare System, West Haven, Connecticut; Digestive Diseases Section, Yale University, New Haven, Connec…. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Recompensation after etiologic cure is increasingly recognized as an achievable state in decompensated cirrhosis, but United States data remain limited. We evaluated the frequency, predictors, and prognostic relevance of recompensation after hepatitis C virus (HCV) cure in United States Veterans with HCV-related decompensated cirrhosis. METHODS: We performed a retrospective cohort study using the Veterans Outcomes and Costs Associated with Liver Disease (VOCAL) cohort. Patients with HCV-related cirrhosis, imaging-documented ascites before direct-acting antiviral therapy, and sustained virologic response were included. The primary outcome was recompensation (per Baveno VII criteria) during follow-up. Fine-Gray regression was used for univariable and multivariable analyses of predictors of recompensation, with death or liver transplantation as competing events. A 24-month landmark analysis assessed subsequent all-cause mortality (Cox regression) and hepatocellular carcinoma (Fine-Gray regression). A separate Fine-Gray analysis evaluated time to documented ascites resolution. RESULTS: Among 1213 eligible patients, 163 (13%) achieved recompensation up to 24 months after direct-acting antiviral initiation. In multivariable analysis, higher baseline albumin independently predicted recompensation, whereas platelet count

Schlagwörter

Stichwörter der Autor:innen

AscitesDecompensated CirrhosisHepatitis C VirusRecompensation

Autor:innen und Institutionen

  • Digestive Diseases Section, VA Connecticut Healthcare System, West Haven, Connecticut; Digestive Diseases Section, Yale University, New Haven, Connecticut.
  • Gastroenterology Section, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania; Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia Pennsylvania.
  • Digestive Diseases Section, VA Connecticut Healthcare System, West Haven, Connecticut; Digestive Diseases Section, Yale University, New Haven, Connecticut. Electronic address: guadalupe.garcia-tsao@yale.edu.

Zitieren

APA

Goyes, D., Rabiee, A., Chong-Lugon, N., Mezzacappa, C., Kaplan, D. E., Taddei, T. H., & Garcia-Tsao, G. (2026). Recompensation After Etiologic Cure in United States Veterans With Hepatitis C Virus–Related Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.08.010

Vancouver

Goyes D, Rabiee A, Chong-Lugon N, Mezzacappa C, Kaplan DE, Taddei TH, et al. Recompensation After Etiologic Cure in United States Veterans With Hepatitis C Virus–Related Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.08.010

BibTeX
@article{Goyes2026,
  author = {Goyes, Daniela and Rabiee, Anahita and Chong-Lugon, Nicolas and Mezzacappa, Catherine and Kaplan, David E and Taddei, Tamar H and Garcia-Tsao, Guadalupe},
  title = {Recompensation After Etiologic Cure in United States Veterans With Hepatitis C Virus–Related Decompensated Cirrhosis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1016/j.cgh.2026.08.010}
}
Kostenlos starten →